Capecitabine combined with immunotherapy as maintenance therapy improves survival in recurrent/metastatic nasopharyngeal carcinoma: a retrospective cohort study
{{output}}
Background: We evaluated the clinical impact of combining capecitabine with immunotherapy (Immu/Cape) compared to immunotherapy monotherapy (Immu) as maintenance in recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) patien... ...
